N/A N=114 Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults
HIV
Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 Fish Oil for HIV-Related Inflamm-aging and Immune Senescence
HIV Infection
Primary: Change in Markers of Immune Senescence Between Baseline Values and Values After 12 Weeks of Supplementation — 1.87; 4.22; -2.83; -1.56 percentage of cells — p=< 0.05
Phase 4 N=42 Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen
Aging-related Inflammation in HIV-infected Patients
Primary: Changes in the Inflammatory Marker IL-6 — 42.5; 40.0; 39.3; 41.1 pg/mL
N/A N=20 Poor Sleep and Inflammation in HIV-Infected Adults
HIV-1-infection · Sleep Deprivation · Inflammation
Primary: Soluble CD14 — 1290; 1196 ng/mL
N/A N=30 HIV-related Insomnia and Inflammation
Hiv · Insomnia
Primary: Change in hsCRP Levels at 24 Weeks — 2.19; 4.47 mg/L — p=0.607
Phase 2 N=81 Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
Coronary Artery Disease · Human Immunodeficiency Virus
Primary: Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks — 8.1; 13.4 Percent change from rest measurement
N/A N=119 Exercise and Inflammation in the Elderly
Inflammation · Insulin Sensitivity
Primary: Insulin Sensitivity — 50.2; 40.7; 57.5; 42.3 μmol/kgFFM/min
Early Phase 1 N=95 Zinc Effect on Inflammation and Cardiovascular Risk in HIV
Inflammation · Cardiovascular Diseases · Zinc Deficiency
Primary: Effect of Zinc Supplementation on Zinc Levels at 24 Weeks in HIV-infected Subjects — 8.60; 33.50 absolute change (μg/dL) — p=<0.01
Phase 2 N=121 Modulation of Immune Activation by Aspirin
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 11/12 — 0.99; 1.03; 0.97 fold change — p=0.70
N/A N=223 Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences
HIV Infections
Primary: Neuropsychological Status (i.e., Cognitive Functioning) — 0.008; .484; -.084; -.482 z-score composites of cognitive domains — p=0.001
Phase 4 N=4 Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV
Chronic Inflammation
Primary: Number of Differentially Expressed Genes — 8.3 Differentially expressed genes
Phase 2 N=45 Targeting Inflammation to Treat Cardiovascular Aging
Vascular Stiffness · Endothelial Dysfunction · Diastolic Dysfunction
Primary: Carotid-femoral Pulse Wave Velocity (CFPWV) — 831.3; 785.1; 538.0; 839.6 cm/sec
Phase 2 N=109 Neuroinflammation and Modulating Factors in Depression and HIV
Depression · HIV
Primary: Change in Patient Health Questionnaire (PHQ)-9 — 5; 7 units on a scale
Phase 2 N=27 Targeting Platelets in Chronic HIV Infection
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 24 — 35.75; -251.40; -101.75 pg/mL
Phase 2 N=43 Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
HIV · Cardiovascular Disease
Primary: Change in CD4 Count From Baseline to Follow-up — -0.085; -0.024; -0.020; -0.090 log cells per mm^3
N/A N=69 Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause
HIV · Inflammation · Obesity
Primary: Time to Rise From a Chair 10 Times (Modified From the Original Short Physical Performance Battery) — -20; -20; -8; -10 percentage change
N/A N=33 Strength Training and Endurance Exercise for LIFE
HIV
Primary: Aerobic Capacity — 0.15; 0.02 Liters/minute
N/A N=1,377 The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'
HIV Positive · Ageing
Primary: The Prevalence of Reported Aches and Pains in the Last Month Across the 3 Age Groups — 473; 224; 188 participants
Phase 2 N=19 Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People
HIV · Vascular Diseases · Cardiovascular Diseases
Primary: Flow-mediated Dilation of the Brachial Artery — 2.25; 3.36 percent dilation of the brachial artery — p=0.52
Phase 2 N=80 The Role of Probiotics in HIV Patients With Immunological Non-Responder
HIV Infections · Immunological Abnormality
Primary: CD4+ Level — 162.3; 50.5; 143.3; 69.9 cell/μL — p=0.02
Early Phase 1 N=76 Autonomic Neuropathy, GI Motility, and Inflammation in HIV
HIV Disease
Primary: Change in Breath Test — 28; 14 ppm
Phase 2 N=54 Lactoferrin Treatment in HIV Patients
HIV Infection
Primary: Number of Participants With at Least One Side Effect, Adverse Event, and Serious Adverse Event — 20; 17; 12; 11 Participants
Phase 2 N=63 Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
HIV Infection · Bone Loss · Osteopenia
Primary: Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels — 0.092; 0.297; 0.122; 0.331 ng/ml
Phase 4 N=56 Effect of Raltegravir on Endothelial Function in HIV-Infected Patients
HIV Infection · Inflammation · Cardiovascular Disease
Primary: Endothelial Function Measured by Brachial Artery Flow-mediated Dilation(FMD) — 3.4; 2.9 millimeters
Phase 2 N=44 Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Inflammation · Coagulation · HIV Infection
Primary: Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 4 Months. — -0.02; 0.09 ln-pg/mL — p=0.26
Phase 2 N=176 Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications
HIV Infections
Primary: Number of Participants Who Reached at Least One Safety Milestone Over the Duration of Study Follow-up (36 Weeks) — 11; 5 Participants — p=0.0367
Phase 1 N=16 Glutathione and Function in HIV Patients
HIV Infection · Erythrocyte Glutathione Deficiency
Primary: Muscle Glutathione Concentration — 0.5; 2.2 micromol/g.Hb
N/A N=34 Pain Inflammation and Cannabis in HIV
HIV Infections · Neuropathic Pain · Cannabis
Primary: Change in Pain Severity Score — 6.44; 6.86; 8; 7.37 score on a scale — p=0.0303
Phase 4 N=33 Mesalamine to Reduce T Cell Activation in HIV Infection
HIV Infections · Sexually Transmitted Diseases · Immune System Diseases
Primary: Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells During the First 12 Weeks of Study — 0.03; -0.01 Log10(percentage of T cells) — p=0.63
N/A N=35 PET/CT Imaging Companion Study To ACTG A5314
HIV · Inflammation · Atherosclerosis
Primary: Change in Arterial FDG Uptake (From Baseline) in the Most Diseased Segment — -0.126; 0.026 TBR